EG24169A - Substituted acid derivatives useful as antidiabetic and antiobesity agents and method - Google Patents

Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

Info

Publication number: EG24169A
Authority: EG; Egypt
Prior art keywords: antidiabetic; acid derivatives; derivatives useful; substituted acid; antiobesity agents
Prior art date: 1999-09-22

Application number

EG20001198A

Other languages

English (en)

Inventor

Peter T Cheng

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-22

Filing date

2000-09-19

Publication date

2008-09-10

2000-09-19 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2008-09-10 Application granted granted Critical

2008-09-10 Publication of EG24169A publication Critical patent/EG24169A/xx

Links

239000002253 acid Substances 0.000 title 1
230000003178 anti-diabetic effect Effects 0.000 title 1
239000000883 anti-obesity agent Substances 0.000 title 1
229940125708 antidiabetic agent Drugs 0.000 title 1
239000003472 antidiabetic agent Substances 0.000 title 1
229940125710 antiobesity agent Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EG20001198A 1999-09-22 2000-09-19 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method EG24169A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15540099P	1999-09-22	1999-09-22

Publications (1)

Publication Number	Publication Date
EG24169A true EG24169A (en)	2008-09-10

Family

ID=22555274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG20001198A EG24169A (en)	1999-09-22	2000-09-19	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

Country Status (28)

Country	Link
US (1)	US7579479B2 (de)
EP (1)	EP1218361B1 (de)
JP (2)	JP4332315B2 (de)
KR (1)	KR100682419B1 (de)
CN (1)	CN1289490C (de)
AR (1)	AR025756A1 (de)
AT (1)	ATE420080T1 (de)
AU (1)	AU782031B2 (de)
BR (1)	BR0014189A (de)
CA (1)	CA2388452C (de)
CO (1)	CO5200832A1 (de)
DE (1)	DE60041343D1 (de)
EG (1)	EG24169A (de)
ES (1)	ES2319097T3 (de)
HK (1)	HK1049337B (de)
HU (1)	HUP0204416A3 (de)
IL (2)	IL147939A0 (de)
MX (1)	MXPA02001847A (de)
MY (1)	MY138525A (de)
NO (1)	NO322500B1 (de)
NZ (1)	NZ516820A (de)
PE (1)	PE20010643A1 (de)
PL (1)	PL364986A1 (de)
RU (2)	RU2279427C2 (de)
TR (1)	TR200200732T2 (de)
TW (4)	TWI260321B (de)
WO (1)	WO2001021602A1 (de)
ZA (1)	ZA200200937B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
TWI260321B (en) *	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP2003530838A (ja)	2000-04-12	2003-10-21	ヒューマンゲノムサイエンシズインコーポレイテッド	アルブミン融合タンパク質
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
PE20020323A1 (es) *	2000-08-22	2002-06-13	Novartis Ag	COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
AR033390A1 (es) *	2000-08-22	2003-12-17	Novartis Ag	Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
EP1354602B1 (de)	2000-12-26	2006-10-04	Sankyo Company, Limited	Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
WO2002076959A1 (en) *	2001-03-23	2002-10-03	Takeda Chemical Industries, Ltd.	Five-membered heterocyclic alkanoic acid derivative
US7105556B2 (en)	2001-05-30	2006-09-12	Bristol-Myers Squibb Company	Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
IL160304A0 (en) *	2001-08-10	2004-07-25	Nippon Chemiphar Co	ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR delta
EP1442028A4 (de) *	2001-11-06	2009-11-04	Bristol Myers Squibb Co	Substituierte säurederivate, die sich als antidiabetika und mittel gegen obesitas eignen, und verfahren
TW200300681A (en)	2001-11-12	2003-06-16	Ono Pharmaceutical Co	Carboxylic acid derivative compound and medicament containing same as active ingredient
KR20040068240A (ko) *	2001-12-14	2004-07-30	노보 노르디스크 에이/에스	호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
ES2425738T3 (es)	2001-12-21	2013-10-17	Human Genome Sciences, Inc.	Proteínas de fusión de la albúmina
AR039090A1 (es) *	2002-03-22	2005-02-09	Novartis Ag	Combinacion de compuestos organicos
US6716842B2 (en)	2002-04-05	2004-04-06	Warner-Lambert Company, Llc	Antidiabetic agents
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
WO2004004665A2 (en)	2002-07-09	2004-01-15	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
MXPA05000279A (es) *	2002-07-09	2005-03-31	Squibb Bristol Myers Co	Derivados heterociclicos sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo.
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AR041481A1 (es)	2002-10-07	2005-05-18	Hoffmann La Roche	Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
US7098235B2 (en)	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
EP1594530A4 (de)	2003-01-22	2006-10-11	Human Genome Sciences Inc	Albuminfusionsproteine
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) *	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10311984A1 (de) *	2003-03-12	2004-09-23	Freie Universität Berlin	Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten
US20060160894A1 (en) *	2003-06-13	2006-07-20	Laboratorios S.A.L.V.A.T.,S.A.	Benzamides as ppar modulators
WO2005000309A2 (en) *	2003-06-27	2005-01-06	Ionix Pharmaceuticals Limited	Chemical compounds
WO2005049589A2 (en) *	2003-10-14	2005-06-02	Cadila Healthcare Limited	Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
DE602004030470D1 (de)	2003-10-24	2011-01-20	Santen Pharmaceutical Co Ltd	Therapeutisches mittel für keratokonjunktive erkrankungen
CA2543555A1 (en)	2003-10-29	2005-05-06	Santen Pharmaceutical Co., Ltd.	Therapeutic agent for keratoconjunctival disorder
US7829552B2 (en)	2003-11-19	2010-11-09	Metabasis Therapeutics, Inc.	Phosphorus-containing thyromimetics
US20070208021A1 (en) *	2004-03-30	2007-09-06	Daiichi Pharmaceutical Co., Ltd.	Phenoxyacetic Acid Derivatives and Drug Comprising The Same
JP2007230868A (ja) *	2004-03-30	2007-09-13	Dai Ichi Seiyaku Co Ltd	二環性化合物及びそれを用いた医薬
DE602004004631D1 (de)	2004-04-01	2007-03-22	Sanofi Aventis Deutschland	Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
US7618981B2 (en) *	2004-05-06	2009-11-17	Cytokinetics, Inc.	Imidazopyridinyl-benzamide anti-cancer agents
EP1758866A1 (de)	2004-06-18	2007-03-07	Wyeth	Verfahren zur herstellung von 6-alkyl-5-arylsulfonyl-dihydrophenanthridinen
KR100739367B1 (ko) *	2004-07-14	2007-07-16	크리스탈지노믹스(주)	설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물
TW200608967A (en)	2004-07-29	2006-03-16	Sankyo Co	Pharmaceutical compositions containing with diabetic agent
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7589088B2 (en)	2004-12-29	2009-09-15	Bristol-Myers Squibb Company	Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en)	2004-12-29	2009-12-22	Bristol-Myers Squibb Company	Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
EP2527337A1 (de)	2005-04-14	2012-11-28	Bristol-Myers Squibb Company	Hemmer des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms
WO2006117743A1 (en) *	2005-05-03	2006-11-09	Ranbaxy Laboratories Limited	Substituted aromatic compounds as antidiabetic agents
US7521557B2 (en)	2005-05-20	2009-04-21	Bristol-Myers Squibb Company	Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
US7488725B2 (en)	2005-10-31	2009-02-10	Bristol-Myers Squibb Co.	Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
FR2896159B1 (fr)	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2897536A1 (fr) *	2006-02-17	2007-08-24	Galderma Res & Dev	Utilisation du muraglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US7919598B2 (en)	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
US7910747B2 (en)	2006-07-06	2011-03-22	Bristol-Myers Squibb Company	Phosphonate and phosphinate pyrazolylamide glucokinase activators
EP2046753A2 (de)	2006-07-06	2009-04-15	Brystol-Myers Squibb Company	Pyridon/hydroxypyridin-11-beta-hydroxysteroid-dehydrogenase-hemmer vom typ i
US7795291B2 (en) *	2006-07-07	2010-09-14	Bristol-Myers Squibb Company	Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US20080009534A1 (en) *	2006-07-07	2008-01-10	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US7727978B2 (en)	2006-08-24	2010-06-01	Bristol-Myers Squibb Company	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2662084A1 (en)	2006-09-07	2008-03-13	Nycomed Gmbh	Combination treatment for diabetes mellitus
KR100958831B1 (ko) *	2006-09-19	2010-05-24	주식회사유한양행	헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
CA2672956C (en) *	2006-10-26	2015-02-10	Amgen Inc.	Calcium receptor modulating agents
TW200904405A (en)	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Pharmaceutical formulations containing an SGLT2 inhibitor
JP2010524953A (ja)	2007-04-17	2010-07-22	ブリストル−マイヤーズスクイブカンパニー	縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
PE20090696A1 (es)	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
AU2008259342B2 (en)	2007-06-04	2014-07-10	Ben-Gurion University Of The Negev Research And Development Authority	Tri-aryl compounds and compositions comprising the same
WO2008154563A1 (en)	2007-06-11	2008-12-18	Bristol-Myers Squibb Company	1, 3 - dihydroxy substituted phenylamide glucokinase activators
CA2725680A1 (en) *	2008-05-30	2009-12-03	Takeda Pharmaceutical Company Limited	Heterocyclic compound
WO2010004319A1 (en) *	2008-07-07	2010-01-14	Astrazeneca Ab	Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt
KR101036406B1 (ko) *	2008-10-24	2011-05-24	박란	축구공
EP2196476A1 (de)	2008-12-10	2010-06-16	Novartis Ag	Antikörperformulierung
US20120046364A1 (en)	2009-02-10	2012-02-23	Metabasis Therapeutics, Inc.	Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CN102740839B (zh)	2009-11-13	2015-05-06	阿斯利康(瑞典)有限公司	立即释放片剂
CN105193761B (zh)	2009-11-13	2019-12-06	阿斯利康(瑞典)有限公司	双层片剂
US20120294936A1 (en)	2009-11-13	2012-11-22	Astrazeneca Uk Limited	Reduced mass metformin formulations
TWI562775B (en)	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
ES2559209T3 (es)	2010-04-14	2016-02-11	Bristol-Myers Squibb Company	Nuevos activadores de la glucocinasa y métodos de uso de los mismos
MX2013002146A (es)	2010-09-03	2013-04-03	Astrazeneca Uk Ltd	Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
TWI631963B (zh)	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2607480C2 (ru)	2011-02-01	2017-01-10	Бристол-Майерс Сквибб Компани	Фармацевтические композиции, содержащие аминосоединение
DK2713722T3 (en)	2011-05-31	2017-07-03	Celgene Int Ii Sarl	Newly known GLP-1 receptor stabilizers and modulators
EP2574607A1 (de)	2011-09-06	2013-04-03	F. Hoffmann-La Roche AG	PDE 10-Modulatoren
UA117574C2 (uk)	2012-11-20	2018-08-27	Лексікон Фармасьютікалз, Інк.	Інгібітори котранспортера натрій-глюкози 1
CA2913791A1 (en)	2013-06-11	2014-12-18	Receptos, Inc.	Novel glp-1 receptor modulators
CN103694195B (zh) *	2013-09-18	2016-04-06	华东师范大学	芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
WO2015068156A1 (en)	2013-11-05	2015-05-14	Ben-Gurion University Of The Negev Research And Development Authority	Compounds for the treatment of diabetes and disease complications arising from same
ES2844573T3 (es)	2014-12-10	2021-07-22	Receptos Llc	Moduladores del receptor de GLP-1
US10829437B2 (en)	2015-04-02	2020-11-10	Obi Pharma, Inc.	Nitrobenzyl derivatives of anti-cancer agents
KR20210065974A (ko)	2018-09-26	2021-06-04	렉시컨 파마슈티컬스 인코퍼레이티드	N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법
CN114981251B (zh) *	2020-01-21	2023-11-21	深圳信立泰药业股份有限公司	一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途
JP7407651B2 (ja) *	2020-04-20	2024-01-04	東ソー・ファインケム株式会社	３－アセトキシスチレンの製造方法
AU2023376551A1 (en)	2022-11-08	2025-04-17	Genfit	Ppar-alpha/gamma agonist for use in the treatment of liver failure

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5036079A (en) *	1989-12-07	1991-07-30	Pfizer Inc.	Hypoglycemic thiazolidinedione derivatives
US5175283A (en) *	1990-06-04	1992-12-29	Bristol-Myers Squibb Company	Azetidin-2-one derivatives as serine protease inhibitors
US5037819A (en) *	1990-06-04	1991-08-06	Bristol-Myers Squibb Company	Azetidin-2-one derivatives as serine protease inhibitors
US5110812A (en) *	1990-06-04	1992-05-05	Bristol-Myers Squibb Co.	Azetidin-2-one derivatives as serine protease inhibitors
US5250677A (en) *	1990-06-04	1993-10-05	Bristol-Myers Squibb Company	Azetidin-2-one derivatives as serine protease inhibitors
JPH05213884A (ja)	1991-06-14	1993-08-24	Upjohn Co:The	新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
GB9113628D0 (en)	1991-06-25	1991-08-14	Ici Plc	Heterocyclic derivatives
TW222626B (de) *	1991-07-22	1994-04-21	Pfizer
US5232945A (en) *	1992-07-20	1993-08-03	Pfizer Inc.	3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5776983A (en) *	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
JPH08325263A (ja) *	1995-05-31	1996-12-10	Sumitomo Metal Ind Ltd	新規２−アミノ−３−フェニルプロピオン酸誘導体
CA2244831A1 (en)	1996-02-02	1997-08-07	John T. Olson	Method of treating diabetes and related disease states
WO1997028149A1 (en)	1996-02-02	1997-08-07	Merck & Co., Inc.	Method for raising hdl cholesterol levels
ATE236137T1 (de)	1996-02-02	2003-04-15	Merck & Co Inc	Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
CA2245524A1 (en)	1996-02-02	1997-08-07	Wei Han	Antidiabetic agents
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
JP3215048B2 (ja) *	1996-04-03	2001-10-02	日本たばこ産業株式会社	プロピオン酸誘導体及びその用途
US5889025A (en) *	1996-05-06	1999-03-30	Reddy's Research Foundation	Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
JP2000515501A (ja)	1996-07-01	2000-11-21	イーライ・リリー・アンド・カンパニー	低血糖化および低脂血化用化合物群
EP0925063A4 (de)	1996-07-01	2000-12-27	Lilly Co Eli	Blutzuckersenkende und lipidsenkende verbindungen
AU719663B2 (en)	1996-12-23	2000-05-11	Merck & Co., Inc.	Antidiabetic agents
WO1999007357A1 (en)	1997-08-08	1999-02-18	Ono Pharmaceutical Co., Ltd.	η-TYPE REGULATORS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
AU8750298A (en)	1997-08-28	1999-03-22	Ono Pharmaceutical Co. Ltd.	Peroxisome proliferator-activated receptor controllers
AU9002798A (en)	1997-09-19	1999-04-12	Ono Pharmaceutical Co. Ltd.	Fused or nonfused benzene compounds
HUP0101022A1 (hu)	1997-10-17	2001-10-28	Aventis Pharmaceuticals Products Inc.	Kinolinszármazékok gyógyászati alkalmazása
CN1280574A (zh)	1997-10-27	2001-01-17	雷迪研究基金会	新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6506757B1 (en) *	1998-03-10	2003-01-14	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
EP1073643B1 (de)	1998-04-23	2004-12-29	Dr. Reddy's Laboratories Ltd.	Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9817118D0 (en) *	1998-08-07	1998-10-07	Glaxo Group Ltd	Pharmaceutical compounds
EP1177187B1 (de)	1999-04-28	2007-07-25	Sanofi-Aventis Deutschland GmbH	Di-aryl-säurederivate als ppar rezeptor liganden
WO2000064876A1 (en)	1999-04-28	2000-11-02	Aventis Pharma Deutschland Gmbh	Tri-aryl acid derivatives as ppar receptor ligands
TWI260321B (en) *	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

2000
- 2000-09-18 TW TW089119155A patent/TWI260321B/zh not_active IP Right Cessation
- 2000-09-18 TW TW093126012A patent/TW200514783A/zh unknown
- 2000-09-18 TW TW093126011A patent/TW200528436A/zh unknown
- 2000-09-18 TW TW094102034A patent/TWI302149B/zh not_active IP Right Cessation
- 2000-09-19 KR KR1020027003723A patent/KR100682419B1/ko not_active Expired - Fee Related
- 2000-09-19 AT AT00965172T patent/ATE420080T1/de not_active IP Right Cessation
- 2000-09-19 HK HK03101528.6A patent/HK1049337B/zh not_active IP Right Cessation
- 2000-09-19 CN CNB008131406A patent/CN1289490C/zh not_active Expired - Fee Related
- 2000-09-19 HU HU0204416A patent/HUP0204416A3/hu unknown
- 2000-09-19 TR TR2002/00732T patent/TR200200732T2/xx unknown
- 2000-09-19 EG EG20001198A patent/EG24169A/xx active
- 2000-09-19 RU RU2002108928/04A patent/RU2279427C2/ru not_active IP Right Cessation
- 2000-09-19 IL IL14793900A patent/IL147939A0/xx active IP Right Grant
- 2000-09-19 PL PL00364986A patent/PL364986A1/xx not_active Application Discontinuation
- 2000-09-19 RU RU2005117879/04A patent/RU2327692C2/ru not_active IP Right Cessation
- 2000-09-19 CA CA002388452A patent/CA2388452C/en not_active Expired - Fee Related
- 2000-09-19 JP JP2001524981A patent/JP4332315B2/ja not_active Expired - Fee Related
- 2000-09-19 ES ES00965172T patent/ES2319097T3/es not_active Expired - Lifetime
- 2000-09-19 EP EP00965172A patent/EP1218361B1/de not_active Expired - Lifetime
- 2000-09-19 BR BR0014189-5A patent/BR0014189A/pt not_active Application Discontinuation
- 2000-09-19 NZ NZ516820A patent/NZ516820A/en unknown
- 2000-09-19 MX MXPA02001847A patent/MXPA02001847A/es active IP Right Grant
- 2000-09-19 WO PCT/US2000/025710 patent/WO2001021602A1/en not_active Ceased
- 2000-09-19 DE DE60041343T patent/DE60041343D1/de not_active Expired - Lifetime
- 2000-09-19 AU AU75935/00A patent/AU782031B2/en not_active Ceased
- 2000-09-21 MY MYPI20004412A patent/MY138525A/en unknown
- 2000-09-21 CO CO00071835A patent/CO5200832A1/es not_active Application Discontinuation
- 2000-09-22 PE PE2000000994A patent/PE20010643A1/es not_active Application Discontinuation
- 2000-09-22 AR ARP000104989A patent/AR025756A1/es not_active Application Discontinuation
2002
- 2002-01-31 IL IL147939A patent/IL147939A/en not_active IP Right Cessation
- 2002-02-01 ZA ZA200200937A patent/ZA200200937B/en unknown
- 2002-03-21 NO NO20021408A patent/NO322500B1/no not_active IP Right Cessation
2005
- 2005-08-22 US US11/155,965 patent/US7579479B2/en not_active Expired - Lifetime
2008
- 2008-12-22 JP JP2008325065A patent/JP2009102360A/ja active Pending

Also Published As

Publication number	Publication date
DE60041343D1 (de)	2009-02-26
TW200528436A (en)	2005-09-01
ES2319097T3 (es)	2009-05-04
JP2003509503A (ja)	2003-03-11
HUP0204416A2 (hu)	2003-04-28
NZ516820A (en)	2004-11-26
AU782031B2 (en)	2005-06-30
TR200200732T2 (tr)	2002-10-21
NO20021408D0 (no)	2002-03-21
US7579479B2 (en)	2009-08-25
JP4332315B2 (ja)	2009-09-16
HK1049337B (zh)	2007-07-27
HK1049337A1 (en)	2003-05-09
ATE420080T1 (de)	2009-01-15
RU2002108928A (ru)	2004-01-10
NO322500B1 (no)	2006-10-16
WO2001021602A1 (en)	2001-03-29
TWI302149B (en)	2008-10-21
RU2327692C2 (ru)	2008-06-27
CO5200832A1 (es)	2002-09-27
EP1218361B1 (de)	2009-01-07
KR100682419B1 (ko)	2007-02-28
KR20020047179A (ko)	2002-06-21
MXPA02001847A (es)	2002-10-23
HUP0204416A3 (en)	2006-01-30
EP1218361A1 (de)	2002-07-03
AR025756A1 (es)	2002-12-11
AU7593500A (en)	2001-04-24
CN1374955A (zh)	2002-10-16
MY138525A (en)	2009-06-30
TW200514783A (en)	2005-05-01
IL147939A (en)	2008-03-20
US20070015797A1 (en)	2007-01-18
CA2388452C (en)	2007-04-03
TW200538446A (en)	2005-12-01
TWI260321B (en)	2006-08-21
PE20010643A1 (es)	2001-08-18
ZA200200937B (en)	2003-07-30
BR0014189A (pt)	2002-08-20
JP2009102360A (ja)	2009-05-14
CN1289490C (zh)	2006-12-13
CA2388452A1 (en)	2001-03-29
PL364986A1 (en)	2004-12-27
IL147939A0 (en)	2002-08-14
RU2005117879A (ru)	2006-11-20
RU2279427C2 (ru)	2006-07-10
NO20021408L (no)	2002-05-14

Publication	Publication Date	Title
EG24169A (en)	2008-09-10	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1442028A4 (de)	2009-11-04	Substituierte säurederivate, die sich als antidiabetika und mittel gegen obesitas eignen, und verfahren
EP1656368A4 (de)	2009-08-26	Als antidiabetika und mittel gegen obesitas geeignete substituierte heterocyclische derivate und verfahren
IL139470A0 (en)	2001-11-25	Oxyiminoalkanoic acid derivatives
SI1371647T1 (en)	2005-10-31	Pyridine-3-carboxylic acid derivatives and their use as intermediates
HUP0200297A3 (en)	2002-09-30	Method for acylating peptides and the glutaminic acid derivatives as acylating agents
EG24140A (en)	2008-08-06	New 3-aryl-2-hydroxypropionic acid derivative
IL140358A0 (en)	2002-02-10	Aminomethylarboxylic acid derivatives
PL334997A1 (en)	2000-03-27	Derivatives or arylosulphonyl-hydroxamic acid
ZA200203367B (en)	2003-09-10	Antidiabetic formulation and method.
GB9806815D0 (en)	1998-05-27	Amino acid derivatives
EP1024130A4 (de)	2004-12-15	Biphenyl-5-alkansäure-derivate und ihre anwendung
HU9801044D0 (en)	1998-07-28	Sulfonyl-amino-carboxylic acid derivatives
IL154031A0 (en)	2003-07-31	Substituted sulfonylaminomethylbenzoic acid derivatives and preparation
HUP0100870A3 (en)	2002-11-28	Alpha-aminoamide derivatives useful as analgesic agents
AU1564001A (en)	2001-05-08	Method and arrangement relating to positioning
IL146629A0 (en)	2002-07-25	Indolylpiperidine derivatives as antihistaminic and antiallergic agents
PL367066A1 (en)	2005-02-21	Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
HRP20000529B1 (en)	2004-12-31	Novel dihydroxyhexanoic acid derivatives
AU2690600A (en)	2000-09-14	2-mercaptocarboxylic acid derivatives
GR3031027T3 (en)	1999-12-31	Piperidineacetic acid derivatives useful as fibrinogen antagonist agent
AU1268400A (en)	2000-06-05	Isothiazolecarboxylic acid derivatives
AU1303201A (en)	2001-06-06	Alkoxyiminoalkanoic acid derivatives
EP1229913A4 (de)	2005-01-19	Substituierte 1-benzazepine und dessen derivate
IL135639A0 (en)	2001-05-20	Novel methylenebisphosphonic acid derivatives